Transgenic MSH overexpression attenuates the metabolic effects of a high-fat diet

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 1, 2007, Pages

  Lee, Michelle ^a   Kim, Andrea ^a   Chua Jr , Streamson C ^a,b   Obici, Silvana ^b,c   Wardlaw, Sharon L ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Hepatic steatosis; Melanocortins; Melanocyte stimulating hormone; Obesity; Proopiomelanocortin

Indexed keywords

CORTICOSTERONE; GLUCOSE; INTERMEDIN; MELANOCORTIN; MESSENGER RNA; PROOPIOMELANOCORTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIMETRY; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENERGY EXPENDITURE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE ACTION; LIPID DIET; LIPID STORAGE; LOW FAT DIET; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WEIGHT GAIN;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; DIET, ATHEROGENIC; EATING; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HOMEOSTASIS; LIPIDS; LIVER; MALE; MELANOCYTE-STIMULATING HORMONES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY; ORGAN SIZE; OXYGEN CONSUMPTION; RESPIRATORY FUNCTION TESTS;

EID: 34547122875     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00555.2006     Document Type: Article

References (62)

1. Adage T, Scheurink AJ, de Boer SF, de Vries K, Konsman JP, Kuipers F, Adan RA, Baskin DG, Schwartz MW, van Dijk G. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats. J Neurosci 21: 3639-3645, 2001.
2. Adan RA, Gispen WH. Brain melanocortin receptors: from cloning to function. Peptides 18: 1279-1287, 1997.
3. Albarado DC, McClaine J, Stephens JM, Mynatt RL, Ye J, Bannon AW, Richards WG, Butler AA. Impaired coordination of nutrient intake and substrate oxidation in melanocortin-4 receptor knockout mice. Endocrinology 145: 243-252, 2004.
4. Benoit SC, Sheldon RJ, Air EL, Messerschmidt P, Wilmer KA, Hodge KM, Jones MB, Eckstein DM, McOsker CC, Woods SC, Seeley RJ. Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. Int J Obes Relat Metab Disord 27: 550-556, 2003.
5. Bradley RL, Mansfield JP, Maratos-Flier E. Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes. Obes Res 13: 653-661, 2005.
6. Butler AA. The melanocortin system and energy balance. Peptides 27: 281-290, 2006.
7. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521, 2000.
8. Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, Cone RD. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 4: 605-611, 2001.
9. Cettour-Rose P, Rohner-Jeanrenaud F. The leptin-like effects of 3-d peripheral administration of a melanocortin agonist are more marked in genetically obese Zucker (fa/fa) than in lean rats. Endocrinology 143: 2277-2283, 2002.
10. Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn D, Rochford JJ, White A, Oliver RL, Millington G, Aparicio SA, Colledge WH, Russ AP, Carlton MB, O'Rahilly S. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY (3-36). Proc Natl Acad Sci USA 101: 4695-4700, 2004.
11. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van Der Ploeg LH. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26: 97-102, 2000.
12. Coll AP, Challis BG, Lopez M, Piper S, Yeo GS, O'Rahilly S. Proopiomelanocortin-deficient mice are hypersensitive to the adverse metabolic effects of glucocorticoids. Diabetes 54: 2269-2276, 2005.
13. Coll AP, Farooqi IS, Challis BG, Yeo GS, O'Rahilly S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 89: 2557-2562, 2004.
14. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571-578, 2005.
15. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24: 155-163, 1999.
16. Dunbar JC, Lu H. Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products. Brain Res Bull 50: 215-221, 1999.
17. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141: 3072-3079, 2000.
18. Farooqi IS, Drop S, Clements A, Keogh JM, Biernacka J, Lowenbein S, Challis BG, O'Rahilly S. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. Diabetes 55: 2549-2553, 2006.
19. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348: 1085-1095, 2003.
20. Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM, Emerson CH, Lechan RM. alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci 20: 1550-1558, 2000.
21. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509, 1957.
22. Gutierrez-Juarez R, Obici S, Rossetti L. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J Biol Chem 279: 49704-49715, 2004.
23. Hamilton BS, Doods HN. Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obes Res 10: 182-187, 2002.
24. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 33: 542-547, 1999.
25. Heijboer AC, van den Hoek AM, Pijl H, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP. Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia 48: 1621-1626, 2005.
26. Hoggard N, Rayner DV, Johnston SL, Speakman JR. Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice. J Mol Endocrinol 33: 693-703, 2004.
27. Huang XF, Han M, South T, Storlien L. Altered levels of POMC, AgRP and MC4-R mRNA expression in the hypothalamus and other parts of the limbic system of mice prone or resistant to chronic high-energy diet-induced obesity. Brain Res 992: 9-19, 2003.
28. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141, 1997.
29. Hwa JJ, Ghibaudi L, Gao J, Parker EM. Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats. Am J Physiol Regul Integr Comp Physiol 281: R444-R451, 2001.
30. Jonsson L, Skarphedinsson JO, Skuladottir GV, Watanobe H, Schioth HB. Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats. J Endocrinol 173: 517-523, 2002.
31. Korner J, Wissig S, Kim A, Conwell IM, Wardlaw SL. Effects of agouti-related protein on metabolism and hypothalamic neuropeptide gene expression. J Neuroendocrinol 15: 1116-1121, 2003.
32. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157, 1998.
33. Legradi G, Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 140: 3643-3652, 1999.
34. Li G, Mobbs CV, Scarpace PJ. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 52: 1951-1957, 2003.
35. Li G, Zhang Y, Wilsey JT, Scarpace PJ. Hypothalamic pro-opiomelanocortin gene delivery ameliorates obesity and glucose intolerance in aged rats. Diabetologia 48: 2376-2385, 2005.
36. Lin J, Choi YH, Hartzell DL, Li C, Della-Fera MA, Baile CA. CNS melanocortin and leptin effects on stearoyl-CoA desaturase-1 and resistin expression. Biochem Biophys Res Commun 311: 324-328, 2003.
37. Liposits Z, Sievers L, Paull WK. Neuropeptide-Y and ACTH-immunoreactive innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamus of the rat. An immunocytochemical analysis at the light and electron microscopic levels. Histochemistry 88: 227-234, 1988.
38. Martin NM, Small CJ, Sajedi A, Liao XH, Weiss RE, Gardiner JV, Ghatei MA, Bloom SR. Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse. Regul Pept 122: 169-172, 2004.
39. Martin NM, Smith KL, Bloom SR, Small CJ. Interactions between the melanocortin system and the hypothalamo-pituitary-thyroid axis. Peptides 27: 333-339, 2006.
40. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 279: R695-R703, 2000.
41. Mizuno TM, Kelley KA, Pasinetti GM, Roberts JL, Mobbs CV. Transgenic neuronal expression of proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes 52: 2675-2683, 2003.
42. Mizuno TM, Makimura H, Mobbs CV. The physiological function of the agouti-related peptide gene: the control of weight and metabolic rate. Ann Med 35: 425-433, 2003.
43. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L. Central melanocortin receptors regulate insulin action. J Clin Invest 108: 1079-1085, 2001.
44. Okamoto H, Obici S, Accili D, Rossetti L. Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest 115: 1314-1322, 2005.
45. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138, 1997.
46. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51: 1337-1345, 2002.
47. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 1: 53-61, 2005.
48. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90: 8856-8860, 1993.
49. Satoh N, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Yoshimasa Y, Nakao K. Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Neurosci Lett 249: 107-110, 1998.
50. Savontaus E, Breen TL, Kim A, Yang LM, Chua SC Jr, Wardlaw SL. Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice. Endocrinology 145: 3881-3891, 2004.
51. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 404: 661-671, 2000.
52. Smart JL, Tolle V, Low MJ. Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice. J Clin Invest 116: 495-505, 2006.
53. Song CK, Jackson RM, Harris RB, Richard D, Bartness TJ. Melanocortin-4 receptor mRNA is expressed in sympathetic nervous system outflow neurons to white adipose tissue. Am J Physiol Regul Integr Comp Physiol 289: R1467-R1476, 2005.
54. Ste Marie L, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 97: 12339-12344, 2000.
55. Tozawa F, Suda T, Dobashi I, Ohmori N, Kasagi Y, Demura H. Central administration of alpha-melanocyte-stimulating hormone inhibits corticotropin-releasing factor release in adrenalectomized rats. Neurosci Lett 174: 117-119, 1994.
56. Tulipano G, Vergoni AV, Soldi D, Muller EE, Cocchi D. Characterization of the resistance to the anorectic and endocrine effects of leptin in obesity-prone and obesity-resistant rats fed a high-fat diet. J Endocrinol 183: 289-298, 2004.
57. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262, 2000.
58. Wardlaw SL. Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 86: 1442-1446, 2001.
59. Wortley KE, Anderson KD, Yasenchak J, Murphy A, Valenzuela D, Diano S, Yancopoulos GD, Wiegand SJ, Sleeman MW. Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab 2: 421-427, 2005.
60. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070, 1999.
61. Zelazowski P, Patchev VK, Zelazowska EB, Chrousos GP, Gold PW, Sternberg EM. Release of hypothalamic corticotropin-releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res 631: 22-26, 1993.
62. Ziotopoulou M, Mantzoros CS, Hileman SM, Flier JS. Differential expression of hypothalamic neuropeptides in the early phase of dietinduced obesity in mice. Am J Physiol Endocrinol Metab 279: E838-E845, 2000.